For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
However, in its drug safety update, the MHRA said the evidence to support further recommendations was limited and it was concluded that anaesthetists should retain the flexibility to provide individualised assessment
GLP-1 Receptor Agonists and Pancreatic Safety Concerns in Type 2 Diabetic Patients: Data From Cardiovascular Outcome Trials
Contact Aesthetics and Medical Lasers of Colorado for a personalized consultation today
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care , vol